Q2 Solutions (NC, USA), a leading clinical trial laboratory services organization, has recently announced it will enter into a global strategic partnership with LGC (Cambridge, UK), a prominent company in the field of life science tools.
In the partnership, Q2 Solutions and LGC have reported they each intend to contribute their extensive experiences and capabilities in small and large molecule bioanalysis in order to support a customer-centric approach. As a result, Q2 Solutions’ customers will gain access to LGC’s bioanalytical facility, one of Europe’s largest dedicated bioanalytical services sites. In exchange, LGC’s customers will be granted access to Q2 Solutions’ bioanalytical facilities in the US and China.
The organizations have announced their ongoing dedication to delivering high quality science and services and expressed how the partnership will allow their customers to enjoy harmonized delivery of bioanalytical testing for their small and large molecule development programs.
Kevin Jones, vice president and general manager of Q2 Solutions has explained: “With LGC’s comprehensive bioanalytical center in Cambridge, UK, we see a synergistic fit between our organizations. This collaboration will offer our clients an expanded suite of bioanalytical capabilities and scientific expertise with an expanded global footprint operating from labs in the US, Europe and China.”
“Over the last couple of years LGC has had a very positive experience collaborating together with Q2 Solutions on behalf of mutual clients. This reinforced the strategic, operational and cultural fit between our organizations and the decision to establish this partnership. We are looking forward to working with Q2 Solutions and deploying this global offering,” concluded Michael van der Merwe, commercial director at LGC.